CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with relapsed or refractory B-cell lymphoid cancers.1 With studies showing that more than 50% of patients had an objective response and that half these patients had sustained disease-free survival, up to 10 distinct CAR T-cell products have received regulatory approval worldwide2,3 for various indications and disease stages of non-Hodgkin's lymphoma, acute lymphoblastic leukemia, and multiple myeloma for approximately 10,000 patients treated each year.3,4 Current research efforts aim to introduce CAR T-cell therapy in earlier disease stages to potentially enhance long-term disease control. A disease that until recently . . .